Clarke A M, Zemcov S J, Wright J M
J Antimicrob Chemother. 1985 Mar;15(3):305-10. doi: 10.1093/jac/15.3.305.
The in-vitro activity of the new parenteral cephalosporins, HR 810 (HR) and BMY-28142 (BMY), was compared with that of other beta-lactam antibiotics, including cefotaxime, against a total of 315 recent clinical isolates and characterized beta-lactamase producers. An agar dilution procedure was used to determine MICs and two inocula (10(4) and 10(6) cfu) were used throughout. Against all species of the Enterobacteriaceae tested, both HR and BMY were as active as, or slightly more active than, cefotaxime. HR differed from cefotaxime mainly in being eight-fold more active against Pseudomonas aeruginosa and two-fold more active against Staphylococcus aureus. BMY was also eight-fold more active than cefotaxime against Ps. aeruginosa but was two-fold less active than the latter against Staph. aureus. Both new compounds had good activity against Haemophilus influenzae, including the beta-lactamase producing strains of that species, and both had poor activity against the Bacteroides fragilis group (MIC90 greater than 128 mg/l).
将新型胃肠外头孢菌素HR 810（HR）和BMY - 28142（BMY）的体外活性与其他β-内酰胺类抗生素（包括头孢噻肟）进行比较，受试对象为总共315株近期临床分离株和已鉴定的β-内酰胺酶产生菌。采用琼脂稀释法测定最低抑菌浓度（MIC），全程使用两种接种量（10⁴和10⁶cfu）。针对所有受试肠杆菌科细菌，HR和BMY的活性与头孢噻肟相当，或略高于头孢噻肟。HR与头孢噻肟的主要区别在于，其对铜绿假单胞菌的活性高八倍，对金黄色葡萄球菌的活性高两倍。BMY对铜绿假单胞菌的活性也比头孢噻肟高八倍，但对金黄色葡萄球菌的活性比后者低两倍。这两种新化合物对流感嗜血杆菌均有良好活性，包括该菌种的产β-内酰胺酶菌株，且对脆弱拟杆菌组活性均较差（MIC90大于128mg/L）。
